Open Access

[Retracted] Rapamycin suppresses the PI3K/AKT/mTOR signaling pathway by targeting SIRT1 in esophageal cancer

  • Authors:
    • Tao Liu
    • Xiangsen Liang
    • Yu Sun
    • Shengzhuang Yang
  • View Affiliations

  • Published online on: November 6, 2023     https://doi.org/10.3892/etm.2023.12288
  • Article Number: 1
  • Copyright : © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Article

Related Articles

Journal Cover

January-2024
Volume 27 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu T, Liang X, Sun Y and Yang S: [Retracted] Rapamycin suppresses the PI3K/AKT/mTOR signaling pathway by targeting SIRT1 in esophageal cancer. Exp Ther Med 27: 1, 2024
APA
Liu, T., Liang, X., Sun, Y., & Yang, S. (2024). [Retracted] Rapamycin suppresses the PI3K/AKT/mTOR signaling pathway by targeting SIRT1 in esophageal cancer. Experimental and Therapeutic Medicine, 27, 1. https://doi.org/10.3892/etm.2023.12288
MLA
Liu, T., Liang, X., Sun, Y., Yang, S."[Retracted] Rapamycin suppresses the PI3K/AKT/mTOR signaling pathway by targeting SIRT1 in esophageal cancer". Experimental and Therapeutic Medicine 27.1 (2024): 1.
Chicago
Liu, T., Liang, X., Sun, Y., Yang, S."[Retracted] Rapamycin suppresses the PI3K/AKT/mTOR signaling pathway by targeting SIRT1 in esophageal cancer". Experimental and Therapeutic Medicine 27, no. 1 (2024): 1. https://doi.org/10.3892/etm.2023.12288